

PCSK9 Inhibitor Therapy: Payer Authorizations in the 12 Months Following FDA Approval

Less than half of patients prescribed PCSK9 inhibitor therapy were approved by their insurance payer



47%
Approved

53%
Rejected

Payer type was the most significant factor associated with approval



Commercial payers had the lowest approval rate and Medicare had the highest

35% of approved patients abandoned the medication



Their out-of-pocket cost was more than twice as much as for patients who purchased the drug